Compare Flux Power Holdings Inc (FLUX) vs 10X Genomics Inc (TXG) Price & Performance

FLUX trades at $0.689, down 3.85% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $6.67 million in 2025 and a negative net income margin of -12.48% in 2026, though revenue remains substantial. Recent news highlights product innovation with the launch of SkyEMS 3.0 and new executive appointments aimed at growth. Analyst consensus is unanimously bullish with 6 buy ratings.

The outlook is mixed: strong analyst support and strategic developments offer upside potential, but persistent losses and bearish technicals pose significant risks. Investors must weigh growth initiatives against profitability challenges and market volatility.

10x Genomics (TXG) trades at $42.56, down 7.07% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company demonstrates strong revenue stability around $640M annually and improving profitability trends, with net losses narrowing significantly from -$255M in 2023 to -$44M in 2025. Recent strategic moves include the Proteintech Genomics acquisition and Cleveland Clinic collaboration to expand multiomics capabilities.

While the company shows promising margin improvement and strategic growth initiatives, investors face valuation concerns with elevated P/S and EV/EBITDA ratios. The mixed analyst sentiment (45% buy, 50% hold) and consensus price target below current levels suggest cautious optimism. Key risks include ongoing profitability challenges and competitive pressures in the life sciences tools market.